JP2016183182A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016183182A5 JP2016183182A5 JP2016114970A JP2016114970A JP2016183182A5 JP 2016183182 A5 JP2016183182 A5 JP 2016183182A5 JP 2016114970 A JP2016114970 A JP 2016114970A JP 2016114970 A JP2016114970 A JP 2016114970A JP 2016183182 A5 JP2016183182 A5 JP 2016183182A5
- Authority
- JP
- Japan
- Prior art keywords
- leukemia
- antibody
- cell
- use according
- antagonistic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 23
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 22
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 9
- 206010057249 Phagocytosis Diseases 0.000 claims description 7
- 230000008782 phagocytosis Effects 0.000 claims description 7
- 230000008685 targeting Effects 0.000 claims description 5
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 4
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 4
- 230000003042 antagnostic effect Effects 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 claims 1
- 102000024905 CD99 Human genes 0.000 claims 1
- 108060001253 CD99 Proteins 0.000 claims 1
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 claims 1
- 101001084266 Homo sapiens Parathyroid hormone 2 receptor Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 102100030869 Parathyroid hormone 2 receptor Human genes 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 210000001539 phagocyte Anatomy 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1132408P | 2008-01-15 | 2008-01-15 | |
| US61/011,324 | 2008-01-15 | ||
| US18978608P | 2008-08-22 | 2008-08-22 | |
| US61/189,786 | 2008-08-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014077464A Division JP6002710B2 (ja) | 2008-01-15 | 2014-04-04 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018006391A Division JP6556271B2 (ja) | 2008-01-15 | 2018-01-18 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016183182A JP2016183182A (ja) | 2016-10-20 |
| JP2016183182A5 true JP2016183182A5 (cg-RX-API-DMAC7.html) | 2017-03-09 |
| JP6280161B2 JP6280161B2 (ja) | 2018-02-14 |
Family
ID=40885608
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543147A Active JP5547656B2 (ja) | 2008-01-15 | 2009-01-15 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2014077464A Active JP6002710B2 (ja) | 2008-01-15 | 2014-04-04 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2016114970A Active JP6280161B2 (ja) | 2008-01-15 | 2016-06-09 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2018006391A Active JP6556271B2 (ja) | 2008-01-15 | 2018-01-18 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2019127276A Active JP6742482B2 (ja) | 2008-01-15 | 2019-07-09 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2020126940A Active JP6960507B2 (ja) | 2008-01-15 | 2020-07-28 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2021166657A Active JP7193601B2 (ja) | 2008-01-15 | 2021-10-11 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2022196360A Active JP7412513B2 (ja) | 2008-01-15 | 2022-12-08 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2023218727A Active JP7638360B2 (ja) | 2008-01-15 | 2023-12-26 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543147A Active JP5547656B2 (ja) | 2008-01-15 | 2009-01-15 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2014077464A Active JP6002710B2 (ja) | 2008-01-15 | 2014-04-04 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018006391A Active JP6556271B2 (ja) | 2008-01-15 | 2018-01-18 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2019127276A Active JP6742482B2 (ja) | 2008-01-15 | 2019-07-09 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2020126940A Active JP6960507B2 (ja) | 2008-01-15 | 2020-07-28 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2021166657A Active JP7193601B2 (ja) | 2008-01-15 | 2021-10-11 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2022196360A Active JP7412513B2 (ja) | 2008-01-15 | 2022-12-08 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| JP2023218727A Active JP7638360B2 (ja) | 2008-01-15 | 2023-12-26 | Ｃｄ４７によって媒介される食作用を操作するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (14) | US8562997B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2242512B1 (cg-RX-API-DMAC7.html) |
| JP (9) | JP5547656B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009205665B2 (cg-RX-API-DMAC7.html) |
| CA (3) | CA2711938C (cg-RX-API-DMAC7.html) |
| DK (3) | DK3056515T4 (cg-RX-API-DMAC7.html) |
| ES (3) | ES2735144T3 (cg-RX-API-DMAC7.html) |
| FI (2) | FI3056515T4 (cg-RX-API-DMAC7.html) |
| PT (3) | PT3056515T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009091601A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070113297A1 (en) * | 2005-09-13 | 2007-05-17 | Yongguang Yang | Methods and compositions for inhibition of immune responses |
| PT3056515T (pt) * | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| HUE050958T2 (hu) | 2008-01-15 | 2021-01-28 | Univ Leland Stanford Junior | Akut mieloid leukémia õssejtek markerei |
| US11072655B2 (en) | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| EP2111869A1 (en) * | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| ES2539141T3 (es) | 2009-05-15 | 2015-06-26 | University Health Network | Composiciones y métodos para tratar cánceres hematológicos dirigiéndose a la interacción SIRPalfa - CD47 |
| EP4134095A1 (en) | 2009-09-15 | 2023-02-15 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| HUE060541T2 (hu) * | 2010-05-14 | 2023-03-28 | Univ Leland Stanford Junior | Humanizált és kiméra monoklonális CD47 elleni ellenanyagok |
| CN102070719A (zh) * | 2010-11-24 | 2011-05-25 | 中国人民解放军第四军医大学 | 一种白血病干细胞靶向可溶性蛋白TrxHis-hCD47 |
| WO2013023015A2 (en) | 2011-08-11 | 2013-02-14 | Albert Einstein College Of Medicine Of Yeshiva University | Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
| US20140140989A1 (en) * | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| SMT201900453T1 (it) * | 2012-02-06 | 2019-11-13 | Inhibrx Inc | Anticorpi anti cd47 e relativi metodi d'uso |
| DK2925782T3 (da) * | 2012-12-03 | 2020-04-06 | Novimmune Sa | Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| JP6572131B2 (ja) | 2012-12-12 | 2019-09-04 | バスキュロックス インコーポレイテッド | 治療用ｃｄ４７抗体 |
| SI2931752T1 (sl) | 2012-12-17 | 2019-12-31 | Trillium Therapeutics Inc. | Zdravljenje bolezenskih celic CD47+ s fuzijami ALFA-FC SIRP |
| AU2014244083B2 (en) * | 2013-03-13 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| CN112245586A (zh) | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| US10064925B2 (en) | 2013-04-29 | 2018-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Use of anti-CD47 agents to enhance immunization |
| CN103665165B (zh) * | 2013-08-28 | 2016-02-24 | 江苏匡亚生物医药科技有限公司 | 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途 |
| NL2011904C2 (en) * | 2013-12-06 | 2015-06-09 | Stichting Vu Vumc | Leukemic stem cell markers. |
| US11046763B2 (en) * | 2014-01-08 | 2021-06-29 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| CA2939293C (en) | 2014-03-11 | 2023-10-03 | The Board Of Trustees Of The Leland Standford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| US10087257B2 (en) | 2014-08-08 | 2018-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | SIRP alpha-antibody fusion proteins |
| GB2532619A (en) * | 2014-08-08 | 2016-05-25 | Alexo Therapeutics Int | Sirp-Alpha Variant Constructs And Uses Thereof |
| PL3656869T5 (pl) | 2014-08-26 | 2025-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Wszczepienie komórek macierzystych z kombinacją środka, który celuje w komórki macierzyste i modulowanie sygnałowania immunoregulatorowego |
| WO2016065245A1 (en) | 2014-10-24 | 2016-04-28 | Incept, Llc | Extra luminal scaffold |
| US10316094B2 (en) | 2014-10-24 | 2019-06-11 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance |
| EP3012271A1 (en) * | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| ES2761861T3 (es) | 2015-01-21 | 2020-05-21 | Univ Leland Stanford Junior | Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| EA035817B1 (ru) | 2015-03-10 | 2020-08-14 | Адуро Байотек, Инк. | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" |
| ES2881771T3 (es) | 2015-08-07 | 2021-11-30 | Alx Oncology Inc | Constructos que tienen un dominio de SIRP-alfa o variante del mismo |
| JP6885606B2 (ja) | 2015-09-18 | 2021-06-16 | アーチ オンコロジー, インコーポレイテッドArch Oncology, Inc. | 治療用ｃｄ４７抗体 |
| CA2999277A1 (en) | 2015-09-21 | 2017-03-30 | Surface Oncology, Inc. | Anti-cd47 antibodies and methods of use |
| RU2022102624A (ru) | 2015-10-01 | 2022-03-10 | Хит Байолоджикс, Инк. | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков |
| MY189819A (en) | 2015-11-27 | 2022-03-10 | Cartherics Pty Ltd | Genetically modified cells and uses thereof |
| RU2627181C2 (ru) * | 2015-12-29 | 2017-08-03 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Экспрессионный плазмидный лентивирусный вектор для гетерологичной экспрессии рекомбинантного человеческого белка cd47 |
| SI3402820T1 (sl) | 2016-01-11 | 2021-04-30 | Forty Seven, Inc. | Humanizirana, mišja ali himerna monoklonska protitelesa proti-CD47 |
| US10257847B2 (en) * | 2016-01-29 | 2019-04-09 | Qualcomm Incorporated | Small cell and communication network reconfiguration based on wireless device capabilities |
| SMT202400438T1 (it) | 2016-04-14 | 2024-11-15 | Ose Immunotherapeutics | Nuovi anticorpi anti-sirpa e loro applicazioni terapeutiche |
| EP3442593A4 (en) * | 2016-04-15 | 2020-01-01 | Trillium Therapeutics Inc. | STIMULATION OF MACROPHAGES IN THERAPY BY CD47 BLOCKING |
| ES2909835T3 (es) | 2016-04-15 | 2022-05-10 | Univ Leland Stanford Junior | Métodos para determinar y alcanzar dosis terapéuticamente efectivas de agentes anti-CD47 en el tratamiento del cáncer |
| EP3448995A1 (en) | 2016-04-25 | 2019-03-06 | Universität Basel | Allele editing and applications thereof |
| WO2017190148A1 (en) | 2016-04-29 | 2017-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| JP7241677B2 (ja) | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｃｄ４７併用療法 |
| EP3493845A4 (en) | 2016-08-03 | 2020-04-15 | The Board of Trustees of the Leland Stanford Junior University | INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| US10995152B2 (en) | 2016-10-26 | 2021-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| US11446315B2 (en) | 2016-11-03 | 2022-09-20 | Pf Argentum Ip Holdings Llc | Enhancement of CD47 blockade therapy by proteasome inhibitors |
| CN118027200A (zh) | 2016-12-09 | 2024-05-14 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| US11384154B2 (en) | 2017-02-06 | 2022-07-12 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
| US10386368B2 (en) | 2017-02-24 | 2019-08-20 | Trustees Of Boston University | Isolation of human lung progenitors derived from pluripotent stem cells |
| CN110381974A (zh) | 2017-02-27 | 2019-10-25 | 沙塔克实验室有限公司 | 基于csf1r的嵌合蛋白 |
| MX2019009812A (es) | 2017-02-27 | 2019-10-14 | Shattuck Labs Inc | Proteinas quimericas basadas en tigit y light. |
| WO2018165015A1 (en) | 2017-03-09 | 2018-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of cd47 pathway |
| CN110650976B (zh) | 2017-04-13 | 2024-04-19 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| US20190062428A1 (en) | 2017-06-19 | 2019-02-28 | Surface Oncology, Inc. | Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof |
| PT3642242T (pt) | 2017-06-21 | 2024-04-16 | Univ Leland Stanford Junior | Parâmetros de dosagem para terapias de direcionamento de cd47 para malignidades hematológicas |
| AU2018308364C1 (en) | 2017-07-26 | 2023-02-16 | Forty Seven, LLC | Anti-SIRP-alpha antibodies and related methods |
| NZ761568A (en) * | 2017-08-02 | 2022-11-25 | Phanes Therapeutics Inc | Anti-cd47 antibodies and uses thereof |
| CN109422811A (zh) | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| EP3692048A4 (en) | 2017-08-30 | 2021-10-20 | Beijing Xuanyi Pharmasciences Co., Ltd. | CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS |
| AU2018351006B2 (en) | 2017-10-18 | 2024-08-29 | Forty Seven, LLC | Anti-CD47 agent-based ovarian cancer therapy |
| US11771764B2 (en) | 2017-11-06 | 2023-10-03 | Pfizer Inc. | CD47 blockade with radiation therapy |
| JP6904434B2 (ja) | 2017-11-29 | 2021-07-14 | 日本電気株式会社 | 情報処理システム、情報処理方法及び記憶媒体 |
| US11180552B2 (en) | 2017-12-01 | 2021-11-23 | Seagen Inc. | CD47 antibodies and uses thereof for treating cancer |
| GB201720077D0 (en) * | 2017-12-01 | 2018-01-17 | Univ Oxford Innovation Ltd | Leukaemic stem cell |
| WO2019126725A1 (en) * | 2017-12-22 | 2019-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for treating age-related diseases |
| PT3752190T (pt) | 2018-02-12 | 2022-11-18 | Forty Seven Inc | Regime anticancerígeno usando anticorpos anti-cd47 e anti-cd20 |
| US11292850B2 (en) | 2018-03-21 | 2022-04-05 | ALX Oncology Inc. | Antibodies against signal-regulatory protein α and methods of use |
| CN110305212A (zh) | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| PE20210342A1 (es) | 2018-05-25 | 2021-02-23 | Alector Llc | Anticuerpos anti-sirpa y metodos de utilizacion de los mismos |
| CA3108795A1 (en) | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | Sirp1a targeted chimeric proteins and uses thereof |
| US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
| CN112739384A (zh) | 2018-09-04 | 2021-04-30 | 延龄草治疗公司 | 用于疾病治疗的cd47阻断和parp抑制 |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| PE20211491A1 (es) | 2018-09-27 | 2021-08-11 | Celgene Corp | PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| KR102871856B1 (ko) | 2018-11-26 | 2025-10-17 | 포티 세븐, 엘엘씨 | c-Kit에 대한 인간화 항체 |
| KR20210094609A (ko) | 2018-11-28 | 2021-07-29 | 포티 세븐, 인코포레이티드 | 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc |
| US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| JP7710997B2 (ja) | 2019-05-31 | 2025-07-22 | エーエルエックス オンコロジー インコーポレイテッド | 免疫チェックポイント阻害剤と組み合わせてｓｉｒｐアルファｆｃ融合によりがんを治療する方法 |
| CN113993899B (zh) | 2019-06-19 | 2024-03-29 | 乐普生物科技股份有限公司 | 抗cd47抗体及其应用 |
| EP3999099A4 (en) * | 2019-07-17 | 2023-08-23 | The Board of Trustees of the Leland Stanford Junior University | COMBINATION OF INTEGRIN-TARGETING FC-KNOTTINE FUSION PROTEIN AND ANTI-CD47 ANTIBODY FOR THE TREATMENT OF CANCER |
| MX2022002613A (es) | 2019-09-03 | 2022-06-02 | Myeloid Therapeutics Inc | Metodos y composiciones para la integracion del genoma. |
| CN114786776A (zh) | 2019-09-18 | 2022-07-22 | 拉姆卡普生物阿尔法股份公司 | 针对ceacam5和cd3的双特异性抗体 |
| CN110755635B (zh) * | 2019-11-14 | 2022-10-11 | 天津大学 | Flu@α-cd47@RGD制剂的合成方法 |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| IL293926A (en) | 2019-12-17 | 2022-08-01 | Pfizer | Antibodies specific for cd47, pd-l1, and uses thereof |
| GB2617474A (en) | 2020-11-04 | 2023-10-11 | Myeloid Therapeutics Inc | Engineered chimeric fusion protein compositions and methods of use thereof |
| JP2023552441A (ja) * | 2020-12-07 | 2023-12-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＳＩＲＰ－αエンゲージャーによる自然免疫細胞のサイレンシング |
| EP4262828A1 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| CN117209608A (zh) | 2020-12-23 | 2023-12-12 | 广东菲鹏制药股份有限公司 | 一种靶向cd47的抗体及其应用 |
| GB2623191A (en) | 2021-03-17 | 2024-04-10 | Myeloid Therapeutics Inc | Engineered chimeric fusion protein compositions and methods of use thereof |
| JP2024515211A (ja) | 2021-04-27 | 2024-04-05 | ファイザー・インク | Ｄｈｆｒ阻害剤を用いたｃｄ４７遮断療法の増強 |
| GB2623653A (en) | 2021-05-11 | 2024-04-24 | Myeloid Therapeutics Inc | Methods and compositions for genomic integration |
| WO2022239485A1 (ja) * | 2021-05-12 | 2022-11-17 | 国立大学法人北海道大学 | 急性骨髄性白血病の遺伝子パネル検査のためのアンプリコンｄｎａライブラリー、キット及びそれらの使用 |
| IL308400A (en) | 2021-05-13 | 2024-01-01 | Alx Oncology Inc | Combined therapies for cancer treatment |
| AU2022289317A1 (en) | 2021-06-10 | 2023-12-14 | Ono Pharmaceutical Co., Ltd. | Method for treating cancer through combination of cd47 inhibitor, immune checkpoint inhibitor, and standard therapy |
| US20250235504A1 (en) | 2021-10-29 | 2025-07-24 | Pfizer Inc. | Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy |
| US20250367255A1 (en) | 2021-11-08 | 2025-12-04 | Pfizer Inc. | Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents |
| CN114262731B (zh) * | 2021-12-22 | 2024-01-23 | 上海国奥源华安生物科技有限公司 | 一种检测膀胱癌细胞用检测试剂盒及其制备方法、膀胱癌细胞的检测方法 |
| EP4479084A1 (en) | 2022-02-14 | 2024-12-25 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| CN120344257A (zh) | 2022-12-09 | 2025-07-18 | 美国辉瑞有限公司 | Cd47阻断剂和抗cd20/抗cd3双特异性抗体组合疗法 |
| KR20250116736A (ko) | 2022-12-09 | 2025-08-01 | 화이자 인코포레이티드 | Cd47 차단제 및 항-bcma/항-cd3 이중특이성 항체 병용 요법 |
| WO2025088065A1 (en) * | 2023-10-25 | 2025-05-01 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Diagnosis and therapy of aml |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1132408A (en) | 1914-06-03 | 1915-03-16 | Joseph Tabor | Train-stopping apparatus. |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| JPS6280161U (cg-RX-API-DMAC7.html) | 1985-11-08 | 1987-05-22 | ||
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US5985660A (en) | 1994-06-15 | 1999-11-16 | Systemix, Inc. | Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation |
| DE69719529T2 (de) * | 1996-10-17 | 2003-12-11 | Immunomedics, Inc. | Nichtantigenes toxinkonjugat und fusionsprotein eines internalisierendes rezeptorsystems |
| US6908763B1 (en) | 1997-08-22 | 2005-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian common lymphoid progenitor cell |
| DE69839492D1 (de) | 1997-09-11 | 2008-06-26 | Chugai Pharmaceutical Co Ltd | Monoklonale antikörper zur apoptosis-induzierung |
| CA2226962A1 (en) | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
| CA2279474C (en) | 1998-07-31 | 2011-01-04 | Stemcell Technologies Inc. | Novel antibody composition for debulking blood and bone marrow samples from cml patients |
| US7696325B2 (en) | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
| CA2375974C (en) | 1999-06-29 | 2010-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian myeloid progenitor cell subsets |
| DE19952960A1 (de) | 1999-11-03 | 2001-05-10 | Mark Andre Freyberg | Verfahren zur Identifizierung von anti-apoptotisch wirksamen Verbindungen |
| GB9930706D0 (en) * | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
| US6733743B2 (en) | 2000-03-06 | 2004-05-11 | University Of Kentucky Research Foundation | Methods to impair hematologic cancer progenitor cells and compounds related thereto |
| TWI242043B (en) | 2000-03-10 | 2005-10-21 | Chugai Pharmaceutical Co Ltd | Polypeptide inducing apoptosis |
| DE10034607A1 (de) * | 2000-07-20 | 2002-02-07 | Gundram Jung | Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren |
| US20050118164A1 (en) * | 2001-03-09 | 2005-06-02 | William Herman | Targeted ligands |
| CA2462653C (en) * | 2001-11-07 | 2016-06-07 | Aya Jakobovits | Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer |
| US20050142539A1 (en) | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
| ATE477276T1 (de) * | 2002-03-01 | 2010-08-15 | Immunomedics Inc | Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen |
| US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| JP3936673B2 (ja) * | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| EP1693385A4 (en) * | 2003-11-11 | 2009-11-04 | Chugai Pharmaceutical Co Ltd | ANTI-CD47 ANTIBODIES HUMANIZED |
| CA2565907A1 (en) | 2004-05-17 | 2005-11-24 | Crucell Holland B.V. | Methods for diagnosis of acute myeloid leukemia |
| EP1841467A4 (en) * | 2005-01-14 | 2009-01-28 | Cytogen Corp | COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES |
| KR101289537B1 (ko) * | 2005-02-15 | 2013-07-31 | 듀크 유니버시티 | 항-ｃｄ19 항체 및 종양학에서 이의 용도 |
| JP2009521206A (ja) * | 2005-04-22 | 2009-06-04 | モルフォテック、インク． | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
| DK1874821T3 (da) | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
| JP2007008895A (ja) | 2005-07-04 | 2007-01-18 | Chugai Pharmaceut Co Ltd | 抗ｃｄ４７抗体とインテグリンリガンドとの併用 |
| JP2005333993A (ja) * | 2005-08-03 | 2005-12-08 | Tohoku Techno Arch Co Ltd | 新規なダイアボディ型二重特異性抗体 |
| US20070113297A1 (en) * | 2005-09-13 | 2007-05-17 | Yongguang Yang | Methods and compositions for inhibition of immune responses |
| US20090191202A1 (en) | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| US7514229B2 (en) * | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
| WO2007121465A2 (en) * | 2006-04-18 | 2007-10-25 | Wellstat Biologics Corporation | Detection of proteins from circulating neoplastic cells |
| JP2009537145A (ja) | 2006-05-15 | 2009-10-29 | バイラル ロジック システムズ テクノロジー コーポレーション | 免疫学的疾患および障害を治療するためのｃｄ４７と関連した組成物および方法 |
| WO2008073316A2 (en) | 2006-12-07 | 2008-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of acute myeloid leukemia stem cells |
| EP2058401A1 (en) | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
| EP2573112A1 (en) * | 2007-10-11 | 2013-03-27 | The Hospital For Sick Children | Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| US11072655B2 (en) | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| HUE050958T2 (hu) | 2008-01-15 | 2021-01-28 | Univ Leland Stanford Junior | Akut mieloid leukémia õssejtek markerei |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| EP2340034B2 (en) | 2008-08-07 | 2019-02-13 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Radioprotectants targeting thrombospondin-1 and cd47 |
| ES2539141T3 (es) | 2009-05-15 | 2015-06-26 | University Health Network | Composiciones y métodos para tratar cánceres hematológicos dirigiéndose a la interacción SIRPalfa - CD47 |
| CN101562733B (zh) * | 2009-05-20 | 2012-09-05 | 中兴通讯股份有限公司 | 将视频采集设备接入次世代网络的装置及方法 |
| EP4134095A1 (en) | 2009-09-15 | 2023-02-15 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| HUE060541T2 (hu) | 2010-05-14 | 2023-03-28 | Univ Leland Stanford Junior | Humanizált és kiméra monoklonális CD47 elleni ellenanyagok |
| AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| JP6572131B2 (ja) | 2012-12-12 | 2019-09-04 | バスキュロックス インコーポレイテッド | 治療用ｃｄ４７抗体 |
| CN112245586A (zh) | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| CA2939293C (en) | 2014-03-11 | 2023-10-03 | The Board Of Trustees Of The Leland Standford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| PT3642242T (pt) | 2017-06-21 | 2024-04-16 | Univ Leland Stanford Junior | Parâmetros de dosagem para terapias de direcionamento de cd47 para malignidades hematológicas |
-
2009
- 2009-01-15 PT PT16160476T patent/PT3056515T/pt unknown
- 2009-01-15 DK DK16160476.4T patent/DK3056515T4/da active
- 2009-01-15 FI FIEP16160476.4T patent/FI3056515T4/fi active
- 2009-01-15 ES ES16160470T patent/ES2735144T3/es active Active
- 2009-01-15 CA CA2711938A patent/CA2711938C/en active Active
- 2009-01-15 CA CA3170329A patent/CA3170329A1/en active Pending
- 2009-01-15 ES ES16160476T patent/ES2740823T3/es active Active
- 2009-01-15 FI FIEP16160470.7T patent/FI3056514T4/fi active
- 2009-01-15 WO PCT/US2009/000319 patent/WO2009091601A1/en not_active Ceased
- 2009-01-15 JP JP2010543147A patent/JP5547656B2/ja active Active
- 2009-01-15 AU AU2009205665A patent/AU2009205665B2/en active Active
- 2009-01-15 EP EP09701993.9A patent/EP2242512B1/en not_active Revoked
- 2009-01-15 PT PT16160470T patent/PT3056514T/pt unknown
- 2009-01-15 EP EP22191294.2A patent/EP4144367B1/en active Active
- 2009-01-15 CA CA3054220A patent/CA3054220C/en active Active
- 2009-01-15 DK DK16160470.7T patent/DK3056514T4/da active
- 2009-01-15 PT PT97019939T patent/PT2242512T/pt unknown
- 2009-01-15 DK DK09701993.9T patent/DK2242512T3/en active
- 2009-01-15 ES ES09701993.9T patent/ES2582340T3/es active Active
-
2010
- 2010-07-15 US US12/837,409 patent/US8562997B2/en active Active
-
2013
- 2013-07-12 US US13/941,287 patent/US20140161825A1/en not_active Abandoned
- 2013-07-12 US US13/941,276 patent/US20140065169A1/en not_active Abandoned
-
2014
- 2014-04-04 JP JP2014077464A patent/JP6002710B2/ja active Active
-
2015
- 2015-07-14 US US14/799,328 patent/US9493575B2/en active Active
- 2015-07-15 US US14/800,474 patent/US9399682B2/en active Active
-
2016
- 2016-02-26 US US15/054,930 patent/US9611329B2/en active Active
- 2016-02-26 US US15/054,914 patent/US9605076B2/en active Active
- 2016-02-26 US US15/054,891 patent/US9624305B2/en active Active
- 2016-06-09 JP JP2016114970A patent/JP6280161B2/ja active Active
-
2017
- 2017-03-10 US US15/456,109 patent/US9765143B2/en active Active
- 2017-07-18 US US15/652,950 patent/US10640561B2/en active Active
-
2018
- 2018-01-18 JP JP2018006391A patent/JP6556271B2/ja active Active
-
2019
- 2019-03-22 US US16/361,567 patent/US20190233515A1/en not_active Abandoned
- 2019-07-09 JP JP2019127276A patent/JP6742482B2/ja active Active
-
2020
- 2020-07-28 JP JP2020126940A patent/JP6960507B2/ja active Active
-
2021
- 2021-04-07 US US17/224,722 patent/US12162939B2/en active Active
- 2021-10-11 JP JP2021166657A patent/JP7193601B2/ja active Active
-
2022
- 2022-05-04 US US17/736,896 patent/US20220267439A1/en not_active Abandoned
- 2022-12-08 JP JP2022196360A patent/JP7412513B2/ja active Active
-
2023
- 2023-12-26 JP JP2023218727A patent/JP7638360B2/ja active Active
-
2024
- 2024-11-04 US US18/936,826 patent/US20250333502A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016183182A5 (cg-RX-API-DMAC7.html) | ||
| Chang et al. | Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells | |
| Sullivan-Chang et al. | Targeting CD22 in B-cell malignancies: current status and clinical outlook | |
| Pegram et al. | IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia | |
| Ronson et al. | Treatment of relapsed/refractory acute lymphoblastic leukemia in adults | |
| CN114634569B (zh) | 高亲和力b7-h6抗体和抗体片段 | |
| Jurcic | What happened to anti-CD33 therapy for acute myeloid leukemia? | |
| JP2020533960A (ja) | 抗ｉｌ１ｒａｐ抗体 | |
| WO2022216965A1 (en) | Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells | |
| JP2016509582A5 (cg-RX-API-DMAC7.html) | ||
| Dabkowska et al. | Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells | |
| FI3890740T3 (fi) | CD70 ja venetoklaksi, BCL-2-estäjä, yhdistelmähoito akuutin myelooisen leukemian hoitoon | |
| Loureiro et al. | Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers | |
| Hebb et al. | Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression | |
| ZA202006504B (en) | Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof | |
| Sermer et al. | Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation | |
| JP2019529416A5 (cg-RX-API-DMAC7.html) | ||
| PH12021552379A1 (en) | Anti-egfrviii antibodies and antigen-binding fragments thereof | |
| Rasche et al. | Novel immunotherapies in multiple myeloma–chances and challenges | |
| Andrade-Gonzalez et al. | Novel therapies in the treatment of hodgkin lymphoma | |
| Valent et al. | Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: perspectives and open issues | |
| Zhang et al. | IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells | |
| Lee et al. | Asymmetric anti-CLL-1× CD3 bispecific antibody, ABL602 2+ 1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release | |
| Tian et al. | Bone-specific enhancement of antibody therapy for breast cancer metastasis to bone | |
| Gao et al. | Auger electron-emitting 111In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123+/CD131− phenotype of leukemia stem cells |